← Back to Volume 4, Issue 1

BCLC Ergothioneine–Curcumin–Piperine Core–Shell Nanolipid Carrier for Synchronized Release, Improved Stability, and Translational Antioxidant–Anti-Inflammatory Synergy

Nour-Eddine Ziraoui, Sebastian Whitmore, Madison Blake
Vol.4, No.1, pp.83-92, 2026 DOI: 10.62051/ijafsr.v4n1.08 April 29, 2026
Download PDF
Abstract: We developed BCLC as a core–shell nanolipid carrier to organize three physicochemically mismatched yet mechanistically complementary actives—ergothioneine (EGT), curcumin, and piperine—within a single delivery architecture. We positioned curcumin in a hydrophobic lipid core, enriched piperine at the interfacial layer, and anchored EGT on a hydrophilic shell, then evaluated particle characteristics, encapsulation efficiency, release behavior, and long-term stability across disclosed embodiments and comparators. The lead embodiment achieved a particle size of 32.6 nm, PDI 0.087, zeta potential −41.2 mV, and encapsulation efficiencies of 96.8%, 95.3%, and 94.7% for EGT, curcumin, and piperine, respectively. At 24 h, cumulative release reached 76.3%, 74.1%, and 77.8%, indicating synchronized release of all three actives, whereas the physical-mixture comparator displayed burst release for EGT and piperine but poor curcumin liberation. After 12 months of storage, active retention remained above 93% in the lead embodiment but fell sharply in several comparators. To position these results within the broader literature, we reviewed representative peer-reviewed and official-source data showing that EGT is absorbed and well tolerated in humans, piperine markedly increases curcumin exposure in human volunteers, curcumin–piperine co-supplementation can improve oxidative-stress endpoints in randomized trials, and core–shell co-delivery systems improve protection and controlled release. Together, these findings support BCLC as a differentiated antioxidant and anti-inflammatory raw-material platform with strong formulation logic and translational potential.
Keywords: BCLC, Ergothioneine, Curcumin, Piperine, Nanolipid carrier, Core–shell delivery, Sustained release, Formulation stability, Antioxidant synergy, Anti-inflammatory formulation
APA Citation: Nour-Eddine Ziraoui, Sebastian Whitmore, Madison Blake (2026). BCLC Ergothioneine–Curcumin–Piperine Core–Shell Nanolipid Carrier for Synchronized Release, Improved Stability, and Translational Antioxidant–Anti-Inflammatory Synergy. International Journal of Agriculture and Food Sciences Research, 4(1), 83-92. https://doi.org/10.62051/ijafsr.v4n1.08

References

  1. BCLC Ergothioneine–Curcumin Synergistic Anti-Inflammatory and Anti-Aging Complex Composition and Preparation Method Thereof.
  2. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998; 64(4):353–356. doi:10.1055/s-2006-957450.
  3. Cheah IK, Tang RMY, Yew TSZ, Lim KHC, Halliwell B. Administration of Pure Ergothioneine to Healthy Human Subjects: Uptake, Metabolism, and Effects on Biomarkers of Oxidative Damage and Inflammation. Antioxid Redox Signal. 2017; 26(5):193–206. doi:10.1089/ars.2016.6778.
  4. Markova NG, Karaman-Jurukovska N, Dong KK, Damaghi N, Smiles KA, Yarosh DB. Skin cells and tissue are capable of using L-ergothioneine as an integral component of their antioxidant defense system. Free Radic Biol Med. 2009; 46(8):1168–1176. doi:10.1016/j.freeradbiomed.2009.01.032.
  5. Hseu YC, Gowrisankar YV, Chen XZ, Yang YC, Yang HL. The Antiaging Activity of Ergothioneine in UVA-Irradiated Human Dermal Fibroblasts via the Inhibition of the AP-1 Pathway and the Activation of Nrf2-Mediated Antioxidant Genes. Oxid Med Cell Longev. 2020; 2020:2576823. doi:10.1155/2020/2576823.
  6. Chen S, McClements DJ, Jian L, Han Y, Dai L, Mao L, Gao Y. Core-Shell Biopolymer Nanoparticles for Co-Delivery of Curcumin and Piperine: Sequential Electrostatic Deposition of Hyaluronic Acid and Chitosan Shells on the Zein Core. ACS Appl Mater Interfaces. 2019; 11(41):38103–38115. doi:10.1021/acsami.9b11782.
  7. Moorthi C, Krishnan K, Manavalan R, Kathiresan K. Preparation and characterization of curcumin-piperine dual drug loaded nanoparticles. Asian Pac J Trop Biomed. 2012; 2(11):841–848. doi:10.1016/S2221-1691(12)60241-X.
  8. Silva-Santana NCF, Rodrigues HCN, Martins TFP, et al. Turmeric supplementation with piperine is more effective than turmeric alone in attenuating oxidative stress and inflammation in hemodialysis patients: A randomized, double-blind clinical trial. Free Radic Biol Med. 2022; 193(Pt 2):648–655. doi:10.1016/j.freeradbiomed.2022.11.008.
  9. Da Paz Martins AS, Jesus RP, de Morais MB, et al. Effect of Curcumin Plus Piperine on Redox Imbalance, Fecal Calprotectin and Cytokine Levels in Inflammatory Bowel Disease Patients: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Nutrients. 2024; 16(15):2450. doi:10.3390/nu16152450.
  10. Zajac IT, Kakoschke N, Kuhn-Sherlock B, May-Zhang LS. The Effect of Ergothioneine Supplementation on Cognitive Function, Memory, and Sleep in Older Adults with Subjective Memory Complaints: A Randomized Placebo-Controlled Trial. Nutraceuticals. 2025; 5(3):15. doi:10.3390/nutraceuticals5030015.
  11. EFSA NDA Panel. Safety of synthetic l-ergothioneine (Ergoneine®) as a novel food pursuant to Regulation (EC) No 258/97. EFSA Journal. 2016; 14(11):4629. doi:10.2903/j.efsa.2016.4629.
  12. U.S. Food and Drug Administration. GRAS Notice No. GRN 000734: Ergothioneine; FDA response letter, May 7, 2018.